A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epstein-Barr-virus-induced-adoptive-T-Cell-Therapy-Eutilex (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; T-cell lymphoma
Focus Therapeutic Use
Sponsors Eutilex

Most Recent Events

11 Nov 2021 Planned number of patients changed from 28 to 72.
17 May 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.
17 May 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight